

## Changes to the CalOptima Approved Drug List, OneCare Formulary and OneCare Connect Formulary Pharmacy & Therapeutics Committee Meeting – February 20, 2020

| Effective<br>Dates | Brand<br>Name†      | Generic Name                               | Drug<br>Class          | Strength                          | Dosage<br>Form               | Committee Action for<br>CalOptima Medi-Cal                 | Committee Action for<br>OneCare/ OneCare<br>Connect  |
|--------------------|---------------------|--|------------------------|-----------------------------------|------------------------------|--|--|
| 4/1/20             | Nourianz            | Istradefylline                             | Parkinson's<br>Disease | 20mg,40mg                         | Tablet                       | PA Required  | Non Formulary  |
| 4/1/20             | Xadago              | Safinamide                                 | Parkinson's<br>Disease | 50mg,100mg                        | Tablet                       | PA Required  | PA Required NSO  |
| 5/1/20             | Zelapar             | Selegiline                                 | Parkinson's<br>Disease | 1.25mg                            | Tablet Dis                   | PA Required  | Non Formulary  |
| 4/1/20             | Vumerity            | Diroximel fumarate                         | Multiple Sclerosis     | 231mg                             | Capsule DR                   | PA Required  | Non Formulary  |
| 4/1/20             | Reblozyl            | Luspatercept-aamt                          | Anemia                 | 25mg,75mg                         | Solution                     | PA Required  | PA Required  |
| 4/1/20             | Duaklir<br>Pressair | Aclidinium bromide-<br>formoterol fumarate | COPD                   | 400mcg-12mcg                      | Aerosol<br>powder            | PA Required  | Non Formulary  |
| 4/1/20             | Trikafta            | Elexacaftor-tezacaftor-<br>ivacaftor       | Cystic Fibrosis        | 100mg-50mg-<br>75mg plus<br>150mg | Tablet                       | PA Required  | PA Required  |
| 4/1/20             | Gamifant            | Emapalumab-Izsg                            | Monoclonal<br>Antibody | 10mg/2mL,<br>50mg/10mL            | Solution                     | PA Required  | PA Required  |
| 4/1/20             | Ozobax              | Baclofen                                   | Muscle Relaxant        | 5mg/5mL                           | Solution                     | PA Required  | Non Formulary  |
| 4/1/20             | Wakix               | Pitolisant                                 | EDS                    | 4.45mg,17.8mg                     | Tablet                       | PA Required  | Non Formulary  |
| 3/1/20             | Trulicity           | Dulaglutide                                | GLP1 agonist           | 0.75mg/0.5mL,<br>1.5mg/0.5mL      | Solution,<br>Pen<br>Injector | Formulary with ST: Must<br>try metformin. QL: 4/28<br>days | Formulary (ST/QL): Must<br>try metformin,<br>metformin/glipizide, or<br>metformin/glyburide. QL:<br>4/28 days  |
| 4/1/20             | Rybelsus            | Semaglutide                                | GLP1 agonist           | 3mg,7mg,14mg                      | Tablet                       | PA Required  | Formulary (ST/QL): Must<br>try metformin,<br>metformin/glipizide, or<br>metformin/glyburide. QL:<br>30/30 days |
| 4/1/20             | Aklief              | Trifarotene                                | Acne Vulgaris          | 0.005%                            | Cream                        | PA Required  | Non Formulary  |

## Changes to the CalOptima Approved Drug List, OneCare Formulary and OneCare Connect Formulary Pharmacy & Therapeutics Committee Meeting – February 20, 2020

| Effective<br>Dates | Brand<br>Name† | Generic Name         | Drug<br>Class  | Strength            | Dosage<br>Form       | Committee Action for<br>CalOptima Medi-Cal | Committee Action for<br>OneCare/ OneCare<br>Connect |
|--------------------|----------------|----------------------|----------------|---------------------|----------------------|--|---|
| 3/1/20             | Pristiq        | Desvenlafaxine       | MDD            | 25mg,50mg,<br>100mg | Tablet ER<br>24 hour | Formulary, QL: 30/30<br>days               | Formulary, QL: 30/30<br>days                        |
| 4/1/20             | Nayzilam       | Midazolam            | Anticonvulsant | 5mg/0.1mL           | Nasal<br>Spray       | PA Required                                | PA Required NSO                                     |
| 4/1/20             | Asparlas       | Calaspargase pegol   | Antineoplastic | 3,750 units/5mL     | Solution             | PA Required                                | PA Required NSO                                     |
| 4/1/20             | Brukinsa       | Zanubrutinib         | Antineoplastic | 80mg                | Capsule              | PA Required                                | PA Required NSO                                     |
| 4/1/20             | Ogivri         | Trastuzumab          | Antineoplastic | 420mg               | Solution             | PA Required                                | PA Required NSO                                     |
| 3/1/20             | Temixys        | Lamivudine-tenofovir | Antiretroviral | 300mg-300mg         | Tablet               | Formulary, QL: 30/30<br>days               | Formulary, QL: 30/30<br>days                        |

NSO = New Starts Only, PA = Prior Authorization, QL = Quantity Limit, DR= Delayed Release, Dis=Disintergrating, ER=Extended Release, COPD=Chronic Obstructive Pulmonary Disease, EDS=Excessive Daytime Sleepiness, GLP1=Glucagon-like peptide-1 receptor, ST=Step Therapy, MDD=Major Depressive Disorder

Page 2 February 20, 2020